<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02653313</url>
  </required_header>
  <id_info>
    <org_study_id>ParvOryx02</org_study_id>
    <nct_id>NCT02653313</nct_id>
  </id_info>
  <brief_title>Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer</brief_title>
  <acronym>ParvOryx02</acronym>
  <official_title>A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oryx GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oryx GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation on safety, tolerability and efficacy of parvovirus H-1 (ParvOryx) in subjects
      suffering from metastatic, inoperable pancreatic cancer with at least one hepatic metastasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigation on safety, tolerability and efficacy of parvovirus H-1 (ParvOryx) in subjects
      suffering from metastatic, inoperable pancreatic cancer with at least one hepatic metastasis.

      Initially four equal doses of ParvOryx will be administered intravenously on four consecutive
      days. Seven to fourteen days after the first intravenous administration the drug will be
      injected directly in a hepatic metastasis of the pancreatic cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of the IMP</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameter: findings in physical examinations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of the IMP</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameters: chosen laboratory parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of the IMP</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameter: ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of the IMP</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameter: adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Humoral immuneresponse to the IMP</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameter: Serum concentration of anti-drug antibodies (ADA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of viral genomes [Vg]</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameter: Cmax in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of viral genomes [Vg]</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameter: AUC in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Shedding of viral genomes [Vg]</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameter: Concentration of Vg in feaces</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Shedding of viral genomes [Vg]</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameter: Concentration of Vg in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Shedding of viral genomes [Vg]</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameter: Concentration of Vg in saliva</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histo-immuno-pathological effects of the IMP in the hepatic metastasis</measure>
    <time_frame>Up to 2 months after treatment beginning</time_frame>
    <description>Parameter: extent of tumor necrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histo-immuno-pathological effects of the IMP in the hepatic metastasis</measure>
    <time_frame>Up to 2 months after treatment beginning</time_frame>
    <description>Parameter: density of tumor infiltrating cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histo-immuno-pathological effects of the IMP in the hepatic metastasis</measure>
    <time_frame>Up to 2 months after treatment beginning</time_frame>
    <description>Parameter: tissue content of cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histo-immuno-pathological effects of the IMP in the hepatic metastasis</measure>
    <time_frame>Up to 2 months after treatment beginning</time_frame>
    <description>Parameter: tissue content of chemokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of virus replication in the hepatic metastasis</measure>
    <time_frame>Up to 2 months after treatment beginning</time_frame>
    <description>Parameters: quantification of NS-1 protein in the metastatic tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular immune response against viral proteins</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameter: ELISPOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular immune response against viral proteins</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameter: FACS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameters: PFS, OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome</measure>
    <time_frame>Up to 6 months after treatment beginning</time_frame>
    <description>Parameter: Serum concentration of CA19-9</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Carcinoma, Pancreatic Ductal</condition>
  <arm_group>
    <arm_group_label>ParvOryx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ParvOryx given intravenously on four consecutive days (day 1 to 4) and intrametastatic six to thirteen days thereafter (day 7, 10 or 14).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parvovirus H-1 (H-1PV)</intervention_name>
    <description>Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.
The total dose levels are: 1E09, 5E09 and 1E10 pfu.</description>
    <arm_group_label>ParvOryx</arm_group_label>
    <other_name>ParvOryx</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age at least 18 year,

          2. Ability to give informed consent,

          3. Histologically confirmed pancreatic ductal adenocarcinoma (PAD) with at least one
             measurable hepatic metastasis according to RECIST 1.1,

          4. Disease progression despite first line therapy (whatever chemotherapy regimen),

          5. Eligibility for second line chemotherapy with gemcitabine,

          6. ECOG performance scale 0 or 1,

          7. Consent for the sampling and investigations of biological specimens as scheduled by
             the trial protocol,

          8. Adequate bone marrow function: neutrophils &gt;1.5 x 1E09/L, platelets &gt;100 x 1E09/L,
             hemoglobin &gt;9.0 g/dL,

          9. Liver function tests (LFT) within the following range: Bilirubin &lt;3 x ULN (Upper Limit
             of Normal); ASAT and ALAT &lt;5 x ULN,

         10. Adequate renal function: Creatinine &lt;1.5 g/dL,

         11. Adequate blood clotting: aPTT &lt;39 sec, INR &lt;1.2,

         12. Normal thyroid function, i.e. TSH, fT3 and fT4 within the normal range (TSH: 0.4 - 4.0
             mU/l, fT3: 2.0 - 4.2 ng/l, fT4: 8 - 18 ng/l)

         13. Negative serology for HIV, HBV and HCV,

         14. Negative Beta-HCG test in blood in woman of childbearing potential,

         15. Use of adequate contraception in both genders, i.e. use of double-effective method of
             contraception for the entire participation in the trial.

        Exclusion Criteria:

          1. Eligibility for surgical treatment,

          2. Symptomatic cerebral, pulmonal, and/or osseous metastases,

          3. Peritoneal carcinosis,

          4. Liver cirrhosis,

          5. Splenectomy,

          6. Relevant respiratory impairment, corresponding to the grade IV or V of the MRC
             Breathlessness Scale (stops for breath after walking about 100 meters or after a few
             minutes on level ground, or too breathless to leave the house, or breathless when
             undressing),

          7. Positive anti-drug antibodies (ADAs) against ParvOryx,

          8. Hospitalization due to other conditions than the pancreatic cancer within the last 3
             months,

          9. Chemotherapy within 2 weeks prior to the first administration of the IMP,

         10. Signs of active, systemic infection within 7 days prior to the study inclusion
             (clinical symptoms (cough, running nose, burning sensation while urinating, apparent
             skin or wound infection) and/or increase of fever and/or deterioration of
             infection-specific laboratory parameters beyond changes apparently driven by the
             underlying pancreatic cancer),

         11. Radiotherapy within 6 weeks prior to the study inclusion,

         12. Contraindications for CT,

         13. Known allergy to iodinated contrast media,

         14. Participation in another interventional trial within the last 30 days,

         15. Presumed contact with pregnant women and/or infants &lt;12 months of age within two
             months after the first administration of the IMP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Huber, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Oryx GmbH &amp; Co. KG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guy Ungerechts, Prof. Dr. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for Tumor Diseases, Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guy Ungerechts, Prof. Dr. Dr.</last_name>
    <phone>+49 6221 56</phone>
    <phone_ext>38718</phone_ext>
    <email>Guy.Ungerechts@nct-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacek Hajda, Dr.</last_name>
    <phone>+49 6221 56</phone>
    <phone_ext>34507</phone_ext>
    <email>Jacek.Hajda@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Center for Tumor Diseases (NCT)</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-WÃ¼rttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Ungerechts, Prof. Dr. Dr.</last_name>
      <phone>+49 6221 56</phone>
      <phone_ext>38718</phone_ext>
      <email>Guy.Ungerechts@nct-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Springfeld, PD Dr. Dr.</last_name>
      <phone>+49 6221 56</phone>
      <phone_ext>38552</phone_ext>
      <email>Christoph.Springfeld@nct-heidelberg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Pancreatic Ductal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

